Selected article for: "animal host and human host"

Author: Balzarini, Jan
Title: Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy
  • Cord-id: 43u7afl3
  • Document date: 2007_1_1
  • ID: 43u7afl3
    Snippet: Several chronic viral infections (such as HIV and hepatitis C virus) are highly prevalent and are a serious health risk. The adaptation of animal viruses to the human host, as recently exemplified by influenza viruses and the severe acute respiratory syndrome coronavirus, is also a continuous threat. There is a high demand, therefore, for new antiviral lead compounds and novel therapeutic concepts. In this Review, an original therapeutic concept for suppressing enveloped viruses is presented tha
    Document: Several chronic viral infections (such as HIV and hepatitis C virus) are highly prevalent and are a serious health risk. The adaptation of animal viruses to the human host, as recently exemplified by influenza viruses and the severe acute respiratory syndrome coronavirus, is also a continuous threat. There is a high demand, therefore, for new antiviral lead compounds and novel therapeutic concepts. In this Review, an original therapeutic concept for suppressing enveloped viruses is presented that is based on a specific interaction of carbohydrate-binding agents (CBAs) with the glycans present on viral-envelope glycoproteins. This approach may also be extended to other pathogens, including parasites, bacteria and fungi.

    Search related documents:
    Co phrase search for related documents
    • acute sars cov respiratory syndrome coronavirus and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute sars cov respiratory syndrome coronavirus and liver lymph: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars cov respiratory syndrome coronavirus and liver lymph node: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and liver serum: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute sars cov respiratory syndrome coronavirus and long term effect: 1, 2, 3, 4, 5, 6, 7
    • acute sars cov respiratory syndrome coronavirus and low affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars cov respiratory syndrome coronavirus and low micromolar range: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute sars cov respiratory syndrome coronavirus and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
    • acute sars cov respiratory syndrome coronavirus and low molecular weight compound: 1
    • acute sars cov respiratory syndrome coronavirus and lower nanomolar: 1
    • acute sars cov respiratory syndrome coronavirus and lowmolecular weight: 1
    • acute sars cov respiratory syndrome coronavirus and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and lymphoid tissue: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and macrophage infect: 1
    • adhesion molecule and liver lymph: 1, 2, 3, 4, 5, 6
    • adhesion molecule and liver lymph node: 1, 2, 3
    • adhesion molecule and liver lymph node sign: 1, 2, 3
    • adhesion molecule and lymph node: 1, 2, 3, 4
    • adhesion molecule and lymphoid tissue: 1